Clinical Trial Update: An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

An open-label, multicenter long-term extension study evaluating etanercept in ankylosing spondylitis to assess long-term safety and efficacy in Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED